The type of vasculitis and the extent of organ involvement guide following treatment. The goals of therapy are 3-fold: To achieve disease remission, to prevent disease recurrence, and to minimize toxicity associated with drug therapy. . In the end, treatment is not without cost, and a high percentage of those surviving will have considerable morbidity related either to the underlying condition or to the treatment itself. New, more specific treatments are under investigation, and have the potential to improve this even further and perhaps reduce the associated morbidity.egységes, osztatlanáltalános orvosango
It is possible to achieve substantial initial control of systemic vasculitis in the majority of pati...
Biological agents represent a valid therapeutic option in patients with severe and/or relapsing vasc...
Biological agents represent a valid therapeutic option in patients with severe and/or relapsing vasc...
Systemic vasculitis is a group of diverse diseases characterized by immune-mediated inflammation of ...
The systemic vasculitides are a complex and often serious group of disorders which, while uncommon, ...
The following chapter outlines the main findings from clinical trials, which provide information on ...
The following chapter outlines the main findings from clinical trials, which provide information on ...
Systemic vasculitides constitute a heterogeneous group of diseases characterized by inflammation of ...
Systemic vasculitides constitute a heterogeneous group of diseases characterized by inflammation of ...
Systemic vasculitides constitute a heterogeneous group of diseases characterized by inflammation of ...
Systemic vasculitides constitute a heterogeneous group of diseases characterized by inflammation of ...
Treatments of vasculitides have progressed markedly over the past few decades. The first attempts to...
ABSTRACTTreatments of vasculitides have progressed markedly over the past few decades. The first att...
Anti-neutrophil cytoplasm antibodies (ANCA) are associated with small vessel vasculitides (AASV) aff...
It is possible to achieve substantial initial control of systemic vasculitis in the majority of pati...
It is possible to achieve substantial initial control of systemic vasculitis in the majority of pati...
Biological agents represent a valid therapeutic option in patients with severe and/or relapsing vasc...
Biological agents represent a valid therapeutic option in patients with severe and/or relapsing vasc...
Systemic vasculitis is a group of diverse diseases characterized by immune-mediated inflammation of ...
The systemic vasculitides are a complex and often serious group of disorders which, while uncommon, ...
The following chapter outlines the main findings from clinical trials, which provide information on ...
The following chapter outlines the main findings from clinical trials, which provide information on ...
Systemic vasculitides constitute a heterogeneous group of diseases characterized by inflammation of ...
Systemic vasculitides constitute a heterogeneous group of diseases characterized by inflammation of ...
Systemic vasculitides constitute a heterogeneous group of diseases characterized by inflammation of ...
Systemic vasculitides constitute a heterogeneous group of diseases characterized by inflammation of ...
Treatments of vasculitides have progressed markedly over the past few decades. The first attempts to...
ABSTRACTTreatments of vasculitides have progressed markedly over the past few decades. The first att...
Anti-neutrophil cytoplasm antibodies (ANCA) are associated with small vessel vasculitides (AASV) aff...
It is possible to achieve substantial initial control of systemic vasculitis in the majority of pati...
It is possible to achieve substantial initial control of systemic vasculitis in the majority of pati...
Biological agents represent a valid therapeutic option in patients with severe and/or relapsing vasc...
Biological agents represent a valid therapeutic option in patients with severe and/or relapsing vasc...